DataMeds Licenses REBOOT Health AI Platform for 666,667 Shares, Claims Nasdaq Equity Compliance

summarizeSummary

DataMeds licensed REBOOT Health AI's platform for 666,667 shares worth $2,000,000, with a true-up that could force more issuance if the stock drops, and says it now meets Nasdaq's $2.5 million stockholders' equity requirement pending formal confirmation; it will also pay REBOOT $50,000 and at least an estimated $100,000 for reconfiguration under the license.

check_boxKey Events · M&A and Partnerships · MEDS

• Updated · Oct 16 · Reuters

  License Paid in Stock With True-Up and Fees

  DataMeds issued REBOOT 666,667 shares valued at $2,000,000; if the market value is below $2,000,000 after 180 days, the company must issue additional shares to cover the shortfall, plus $50,000 cash and a revenue-sharing agreement. Under the license it will also pay REBOOT at least an estimated $100,000 for reconfiguration.

• Exclusive REBOOT Platform License Signed

  Effective October 13, 2026, DataMeds obtained an exclusive U.S. license to REBOOT Health AI's patents and platform, limited to its direct-to-consumer GLP-1 weight-management business; it gets no source code and cannot modify the platform.

• Company Claims Nasdaq Equity Compliance

  After converting about $1.5 million of vendor payables to stock, issuing 636,328 Helomics shares, extinguishing roughly $18.7 million of debt, and the REBOOT issuance, DataMeds says it holds more than $2,500,000 in stockholders' equity and awaits Nasdaq's formal confirmation.

• Delisting Risk Not Fully Cleared

  Nasdaq will continue monitoring the stockholders' equity requirement, and a shortfall at the next periodic report could subject the company to delisting proceedings.

auto_awesomeAnalysis · MEDS · Trade & Services

DataMeds is paying for an exclusive U.S. license to REBOOT Health AI's platform with stock, not cash — 666,667 shares valued at $2,000,000, plus a 180-day true-up that forces the company to issue more shares if the stock falls below that value, and it will pay REBOOT $50,000 and at least an estimated $100,000 for reconfiguration under the license. That structure shifts the risk of a declining share price onto the company's existing holders, who already face the dilution path disclosed in the October 13 information statement. The license itself is narrow: it covers only the company's direct-to-consumer GLP-1 weight-management business, excludes sales to healthcare providers, and gives DataMeds no source code or ability to modify the platform. The more consequential item is the Nasdaq disclosure: after converting roughly $1.5 million of vendor payables into stock, issuing 636,328 shares for Helomics, extinguishing about $18.7 million of debt in the September 17 settlement, and issuing the REBOOT shares, the company says it now has more than $2,500,000 in stockholders' equity and is waiting for Nasdaq's formal confirmation. That is a claim, not a confirmation — Nasdaq will keep monitoring, and a shortfall at the next periodic report could restart delisting proceedings. The company reported a $26.1 million loss and going-concern doubt in its Q2 10-Q, so the equity cure is largely accounting-driven rather than operational.